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Predictive value of the Status Epilepticus
Severity Score (STESS) and its components
for long-term survival
Preben Aukland1†, Martin Lando1†, Ole Vilholm2, Elsebeth Bruun Christiansen2 and Christoph Patrick Beier1,3,4*
Abstract
Background: The “Status Epilepticus Severity Score” (STESS) is the most important clinical score to predict in-hospital
mortality of patients with status epilepticus (SE), but its prognostic relevance for long-term survival is unknown. This
study therefore examined if STESS and its components retain their prognostic relevance beyond acute treatment.
Methods: One hundred twenty-five non-anoxic patients with SE were retrospectively identified in two hospitals
between 2008 and 2014 (39.2 % refractory SE). Patients’ treatment, demographic data, date of death, aetiology of SE,
and the components of the STESS (age, history of seizures, level of consciousness and worst seizure type) were
determined based on the patients’ records.
Results: In 94.4 % of patients, SE was treated successfully; in-hospital mortality rate was 12 %. The overall mortality was
42 % after median follow-up of 28.1 months. The survival plateaued after about 3 years, all patients with progressive brain
diseases (n = 4) died within one year. In-hospital mortality correlated highly significantly with STESS, the optimal cut-off
was 4. With respect to long-term outcome, STESS correlated significantly with overall mortality though with lower odds
ratios. When looking only at patients that survived the acute phase of treatment, only the STESS components “level of
consciousness” (at admission), “coma” as worst seizure type, and “age” reached a statistical significant association with
mortality. In these patients, STESS with a cut-off of 4 was not significantly associated with survival/mortality. Aetiology of
SE was insufficient to explain the weak association and the high mortality after discharge alone.
Conclusion: STESS at onset of SE reliably assessed in-hospital mortality, and was indicative for overall survival. However,
STESS did not allow correct estimation of mortality after discharge. The high mortality after discharge and high overall
mortality of patients diagnosed with SE was not explained by progressive brain disorders alone. Further research is
needed to understand the causes for high overall mortality after SE and putative prognostic factors.
Keywords: Epilepsy, Mortality, Long-term, Short-term, STESS
Background
Status epilepticus (SE) is a serious neurological condition
with significant acute mortality of 7–39 % and early
treatment is of crucial importance [1–6]. The manage-
ment and treatment of patients presenting with SE is
widely debated. The treatment ranges from benzodiaze-
pines, different anti-epileptic drugs to coma induction
[7, 8]. Because of the clinical heterogeneity of the affected
patients [9] and the lack of established prognostic factors,
the prediction of the clinical outcome and survival of SE
remains difficult. Rossetti et al. therefore developed the
“Status Epilepticus Severity Score” (STESS, Additional
file 1: Table S1) in the purpose to predict in-hospital
mortality [10]. The score was designed to give the
clinician an estimate of in-hospital mortality of each
individual patient, based on four outcome predictors
(“age”, “history of seizures”, “seizure type”, “extent of con-
sciousness impairment”). With a maximum score of 6,
Rossetti et al. found an optimal cut-off value at ≥3 with a
sensitivity of 0.94 and specificity 0.60. Negative predictive
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value (NPV) was 0.97 and positive predictive value (PPV)
was 0.39 [11]. STESS is a clinically used score to predict
outcome after SE and has been externally validated in a sec-
ond study [12]. In this confirmatory study, components
“history of seizures” and “extent of consciousness impair-
ment” but not “age” and “generalised convulsive seizures at
SE onset” were significantly associated with higher odds for
death. With a score of ≥4, the optimal cut-off for predicting
in-hospital mortality was higher in this cohort [12].
Leitinger et al. recently developed a new “Epidemi-
ology-based Mortality Status Epilepticus Score” (EMSE)
that initially included a combination of six clinical
parameters: aetiology, age, comorbidity, EEG, duration
and level of consciousness. The authors concluded
that the combination of aetiology, age, level of conscious-
ness, +/−EEG (EMSE-EACE/EMSE-EAC) was in many
ways superior to predict in-hospital mortality than STESS
(≥3 and ≥4) [13]. However, a very recent study showed no
significant difference between STESS and EMSE-EAC or
EMSE-EACE [14].
With SE with respect to mortality and functional sta-
tus, the long-term outcome after discharge of patients is
essentially unknown. Hauser and co-workers studied a
cohort of paediatric and adult patients surviving SE at
least for 30 days. They followed them until death or
end-of-study and found a long-term mortality of 40 %
[15]. Ristic et al. reported a mortality rate of 22.2 % in a
cohort of patients treated in a tertiary reference centre.
Unfortunately, follow up data was available for only
32.8 % of the surviving patients [16]. Apart from patients
with progressive neurological diseases (typically brain
tumours), it is often unknown why patients die several
months after SE. If and how the consequences of pro-
longed SE, e.g. neuronal death due to excitotoxicity or
alteration of neuronal networks, contribute to the high
mortality is unknown [9]. Given that SE treatment often
includes treatment at intensive care units (ICU), which
is associated with significant mortality [17, 18], prognos-
tic factors and scores allowing determining long-term
survival after SE are of high importance.
This study therefore aimed at determining the accur-
acy of STESS on long-term survival based on a popula-
tion of patients presenting with SE at admission or
during hospital stay, treated in two academic centres in
Southern Denmark.
Methods
Patients and ethics
All identifiable patients with SE who have been
treated at the Regional Hospital of Vejle (August
2008 – October 2013) and the University Hospital of
Odense (August 2008 to March 2014) were included.
Both hospitals are regional referral centre for patients
with SE. The study was approved by the local and
national authorities for data security (Sundhedsstyrelsen,
3-3013-696/1) and evaluated by the local ethics commit-
tee. The adult patients (≥18 years) were retrospectively
identified based on ICD-10 codes at discharge (G41X) or
documented SE in the patient records.
Inclusion criteria
On-going clinical or EEG-verified seizures for more than
five minutes or repetitive seizures without normalization
of consciousness in-between [7]
Age of 18 or older
Exclusion criteria
Patients younger than 18
An-/hypoxic-ischemic encephalopathy (n = 10)
The patients’ records were retrospectively analysed.
The patients’ journals were used to score each patient
according to STESS [10]. In addition, aetiology (cate-
gorized as proposed by the International League
Against Epilepsy, ILAE [19]) was assessed. In-hospital
mortality was defined as death under acute treatment.
Patients discharged from hospital to ambulant pallia-
tive care units were considered as “survivors of acute
treatment”. Refractory patients were defined as pa-
tients that did not show prompt response to first-
and second-line treatment with phenytoin, valproate,
phenobarbital, or levetiracetam. The mortality after
discharge was determined using the date of death reg-
istered in the Danish Civil Register, available in the
patient records of deceased patients.
Statistics
The primary, predefined outcome of the study was
STESS’ ability to predict in-hospital and overall mortality
of SE patients. To determine differences of the prognos-
tic impact of the STESS components Odds ratio and
Pearson’s Chi-square were used. The 95 % confidence
interval (CI) of Odd’s ratio was determined as described
in [20]. Table 1 was analyzed using Chi-square tests,
Fisher’s exact test, and student-t test. P-values ≤0.05
were considered significant, values were not corrected
for multiple testing. The ability of STESS to separate
survivors from non-survivors in the acute phase and
after discharge was illustrated using receiver-operating
characteristic curves (ROC). The optimal cut-off point
of the STESS regarding sensitivity and specificity for pre-
diction of death were calculated using Youden’s index
(Youdens index J = Sensitivity + Specificity – 1). The
confidence interval (CI) of ROC was calculated as de-
scribed in [21]. Sensitivity and specificity was found and
used in calculating NPV and PPV at each cut-off. Long-
term survival was addressed using Kaplan-Meier estima-
tor and compared using log-rank test. Statistical analyses
were performed using SPSS 22.0 and Microsoft Excel.
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Results
Patient demographics
The demographics and baseline characteristics of all
included patients are summarized in Table 1. The mean
time of follow up was 30 months (range: 1.5–75.5 months);
median follow-up was 28.1 months. The aetiology was
classified according to the ILAE categorization [19] and
spread among the categories, though very few of the
patients had symptomatic seizures due to progressive
CNS disorders. Data on STESS components (Additional
file 1: Table S1), outcome at end-of-study, outcome at dis-
charge, and acute treatment (incl. narcosis) were available
for all patients.
STESS and in-hospital mortality
Seizures could be terminated in 94.6 % of the patients.
22 % of the patients were treated in the ICU with deep
sedation typically resulting in a burst-suppression pat-
tern in the EEG (Table 1). By the time of discharge 12 %
of the patients died (Table 2A). Of these 15 patients, 7
patients died due to refractory SE, where the seizures
could not be terminated. 8 patients died after SE because
of complications or from underlying SE aetiology. The
complications that led to death were sepsis (2 patients)
and multiple organ failure (1 patient). The underlying
fatal SE aetiologies were encephalitis (1 patient), intra-
cranial haemorrhage (2 patients), meningitis (1 patient),
and brain tumour (1 patient).
All components of STESS were significantly associated
with higher odds for death at the time of discharge
(Table 2A). Notably, in the category “worst seizure type”,
no differences between patients presenting with general-
ized convulsive seizures and simple/complex-partial
seizures were found. Patients presenting in coma (i.e.
without apparent clinical seizures) had a substantially
increased mortality. Determination of Youden’s index
identified 4 as optimal cut-off in this patient cohort
(Fig. 1a). Of the patients with a STESS less than 4, 80/82
Table 1 Patient population
Characteristics Total cohort Non-survivors Survivors P-value
n = 125 (%) n = 58 (42 %) n = 67 (58 %)
Gender, n (%)
Male 64 (51) 36 (62) 28 (42) 0.02*
Female 61 (49) 22 (38) 29 (58)
Age, year (mean ± SD) 62.9 ± 17.5 69.8 ± 15.7 56.9 ± 16.8 <0.01§
SE aetiology grouped according to the international League Against Epilepsy, n (%)
Acute symptomatic seizures 48 (38) 27 (46) 21 (31) 0.16*
Remote symptomatic unprovoked seizures 26 (21) 9 (16) 16 (24)
Symptomatic seizures due to progressive CNS disorders 4 (3) 3 (5) 1 (2)
Unprovoked seizures of unknown aetiology 47 (38) 19 (33) 29 (43)
Refractory SE 49 (39) 29 (50) 20 (30) 0.02*
Seizure termination, n (%) 118 (94) 51 (88) 67 (100) 0.003#
Narcosis 27 (22) 15 (26) 12 (18) 0.28*
STESS at onset of SE, n (%)
Level of consciousness
Awake/somnolent 67 (54) 22 (38) 45 (67) 0.01*
Stuporous/comatose 58 (46) 36 (62) 22 (33)
Worst seizure type
Simple or complex/absence 69 (55) 14 (24) 23 (34) 0.02*
Generalized convulsive 37 (30) 28 (48) 41 (61)
NCSE in coma 19 (15) 16 (28) 3 (4)
Age ≥ 65 years 60 (48) 37 (63) 23 (34) 0.001*
History of seizures 75 (60) 27 (46) 23 (34) 0.16*
STESS ≥ 3 64 (51) 46 (79) 18 (27) <0.001
STESS ≥ 4 82 (66) 55 (95) 27 (40) <0.001
*Chi-square test
#Fisher’s exact test
§t-test
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Table 2 STESS components of survivors and non-survivors
Analysis of survival at discharge/in-hospital mortality
A. STESS at Onset of SE Survivors (n = 110) Non-survivors (n = 15) Odds Ratio (95 % CI) P-value
Level of consciousness n(%)
Awake/somnolent 64(58) 3(20) Reference
Stuporous/ comatose 46(42) 12(80) 5.6 (1.4–21) 0.006
Worst seizure type n(%)
Simple or complex/absence 35(32) 2(13) Reference
Generalized convulsive 66(60) 3(20) 0.8 (0.1–4.9) 0.80
NCSE in coma 9(8) 10(67) 19.4 (3.6–104) 0.0001
Age n(%)
< 65 years 61(55) 4(27) Reference
≥ 65 years 49(45) 11(73) 3.4 (1–11.4) 0.03
History of seizures n(%)
Prior seizures 71(65) 4(27) Reference
No prior seizures 39(35) 11(73) 5.0 (1.5–16.7) 0.005
Analysis of overall survival at end-of-study
B. STESS at Onset of SE Survivors (n = 67) Non-survivors (n = 58) Odds Ratio (95% CI) P-value
Level of consciousness. n(%)
Awake/somnolent 45(67) 22(38) Reference
Stuporous/ comatose 22(33) 36(62) 3.4 (1.6–7) 0.001
Worst seizure type. n(%)
Simple or complex/absence 23(35) 14(24) Reference
Generalized convulsive 41(61) 28(48) 1.1 (0.5–2.5) 0.78
NCSE in coma 3(4) 16(28) 8.7 (2.2–35.6) 0.001
Age. n(%)
< 65 years 44(66) 21(36) Reference
≥ 65 years 23(34) 37(64) 3.4 (1.6–7) 0.001
History of seizures. n(%)
Prior seizures 44(66) 31(53) Reference
No prior seizures 23(34) 27(47) 1.7 (0.8–3.4) 0.16
Analysis of survival of patients that survived acute SE
C. STESS at Onset of SE Survivors (n = 67) Non-survivors (n = 43) Odds Ratio (95 % CI) P-value
Level of consciousness. n(%)
Awake/somnolent 45 (67) 19(44) Reference
Stuporous/ comatose 22 (33) 2456) 2.6 (1.2–5.7) 0.017
Worst seizure type. n(%)
Simple or complex/absence 23(34) 12(28) Reference
Generalized convulsive 41(63) 25(58) 1.2 (0.5–2.8) 0.72
NCSE in coma 3(3) 6(14) 3.8 (0.8–18) 0.08
Age. n(%)
< 65 years 44(66) 17(40 Reference
≥ 65 years 23(34) 26(60) 2.9 (1.3–6.4) 0.007
History of seizures. n(%)
Prior seizures 44(66) 27(63) Reference
No prior seizures 23(34) 16(37) 1.1 (0.5–2.5) 0.76
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patients survived, while 12/42 patients with STESS ≥ 4
died. This gave a high negative predictive value of 98 %
and a positive predictive value of 30 % (Fig. 1a).
STESS and survival after discharge
After a median follow-up of 28.1 months, the overall
mortality was 42 % (in-hospital mortality: 12 %). The
prognostic significance of STESS for long-term outcome
has not been studied yet. We therefore analysed the
association of STESS and its components with overall
survival. The components of STESS were significantly
associated with higher odds for death at end-of-study,
except for history of previous seizures (Table 2B). Still,
the Odds’ ratios for overall mortality at end-of-study
were lower than for at the time of discharge (“in-hospital
mortality”). “Worst seizure type” remained highly
predictive for survival but the differentiation between
“generalized convulsive seizures” and “simple/complex-
partial seizures” remained without prognostic signifi-
cance. Determination of Youdens’ index showed that a
cut-off for analysis of 3 was slightly better than a cut-off
of 4. Using 3 as cut-off, the calculated NPV of 72 % was
considerably lower than at discharge, the PPV was 66 %.
The sensitivity of STESS ≥ 3 for bad outcome was 0.69,
the specificity 0.31 (Additional file 1: Table S2). When
using the optimal cut-off for in-hospital (STESS ≥ 4)
survival, the average survival time was 48.7 months
(CI: 40.9–56.5 months) and significantly longer than
for patients with a non-favourable score (19.6 months,
CI: 11.5–29.4 months, p < 0.001, Fig. 2a; b shows the
same analysis with a cut-off of ≥3). The difference between
patients with a favourable and non-favourable STESS be-
came even more pronounced when looking at patients
with refractory SE only (Additional file 2: Figure S1).
The analysis of overall survival includes both, in-
hospital mortality and death after discharge from hospital.
The mortality of the 110 patients that survived acute treat-
ment in the hospital was 39.1 %. To study if the single
components of STESS retained prognostic relevance
beyond the acute phase of treatment, we analysed the out-
come of patients that survived acute treatment of SE and
could be discharged alive from hospital. With a cut-off of
4, STESS was not associated any more with survival after
discharge (p = 0.29). The STESS components (assessed at
onset of SE) “age”, “level of consciousness”, and worst
seizure type “coma at onset of SE” remained associated
with long-term outcome though with a low odds ratio
(Table 2C). “Previous seizures” and the differentiation
A B
Fig. 1 a-b ROC plotting sensitivity versus 1-specificity for each cut-off value with a diagonal reference line. The table below each ROC curve gives
sensitivity, specificity, NPV, PPV, and Youdens index. a ROC for patients’ death under treatment in the hospital (in-hospital mortality) b ROC for patients
that were discharged alive from hospital
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between “generalized convulsive seizures” and “sim-
ple/complex-partial seizures” as “worst seizure type”
were without prognostic relevance (Table 2C). Figure 1b
shows ROC curve for patients that could be discharged
from hospital, which illustrates the low sensitivity and
specificity for patients’ survival after discharge.
Aetiology and long-term survival
Although components of STESS remained predictive for
the overall survival of SE patients also after discharge,
STESS (cut-off 4) did not reach statistical significance.
In contrast to e.g. the EMSE, STESS does not directly
consider SE aetiology, which may be one possible cause
for the failure of STESS to predict survival after dis-
charge of the hospital [13]. We therefore performed an
additional, exploratory study on the impact of aetiology
on outcome after SE. When looking at overall survival of
the total population, we could see differences depending
on the underlying aetiology (defined according to ILAE
categorisation): All 4 patients suffering from progressive
diseases died rapidly (Fig. 2c). The patients with seizures
due to unknown aetiology showed intermediate survival,
while patients belonging to the other groups (acute,
symptomatic seizures, remote, symptomatic, unprovoked
seizures) showed similar, better long-term outcome.
Notably, the differences between patients with unknown
aetiology and the two other groups with more favourable
outcome disappeared when looking at patients that sur-
vived acute phase of SE (Fig. 2d), mainly due to the high
mortality of patients with acute symptomatic seizures
(11 out of 15 patients that died in the hospital). Still, the
mortality of all patients remained high and plateaued
after about 3 years (Fig. 2c, D). Further, we looked at the
impact of age on the overall outcome given that a sub-
stantial mortality is not uncommon in high age. The
survival curves of patients above and under the age of
A B
D E
C
Fig. 2 Kaplan-Meier estimator of survival. The small vertical tick-marks indicate patients that were alive at the time point of analysis. a Kaplan-Meier plot
presenting overall survival at end-of-study for patients with a favourable STESS 0–3 (grey line) and an unfavourable STESS of 4–6 (black line). b Kaplan-Meier
plot presenting overall survival at end-of-study for patients with a favourable STESS 0–2 (grey line) and an unfavourable STESS of 3–6
(black line). c Kaplan-Meier plot presenting overall survival depending on aetiology. d Kaplan-Meier plot presenting survival depending on
aetiology of all patients that were discharged alive from hospital. e Kaplan-Meier plot presenting overall survival depending on age at
diagnosis above or below 65 years
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65 years significantly differed but showed the same plat-
eau after about 3 years (Fig. 2e).
Discussion
An important finding of this study is the high mortality
after discharge. After an average follow-up of 30 months,
42 % of our patients died. Our mortality and the data
published by Logroscino et al. appear to be in the same
range despite of the differences in the patient popula-
tions. Logroscino et al. analysed 145 patients (including
paediatric patients) that survived 30 days after diagnosis
of SE and found a 10-year mortality of 43 % [15]. These
rates were substantially higher than the mortality rates
of 22.2 % described by Ristic et al. [16]. However, Ristic
et al. reported incomplete follow-up data in more than
2/3 of the patients, which may explain this difference.
The high mortality also prompts the question if our co-
hort was biased. We assume that the study population in-
cluded all patients that required intravenous 2nd line
treatment as well as all patients with refractory (refractory
to 2nd line treatment) and super-refractory SE (refractory
to narcosis), because all these patients are treated in the
neurological departments. However, it is likely that an un-
known number of patients with prompt success of 1st line
treatment with benzodiazepines (e.g. patients with SE due
to alcohol withdrawal) were not included in this study due
to incorrect use of ICD-10 codes in the emergency depart-
ments. However, this potential minor bias did not lead to
a higher proportion of severely ill patients included in this
study and does therefore not explain the high overall mor-
tality after SE in our cohort. Our cohort comprised 40 %
patients with refractory SE (defined by failure of 2nd line
therapy), which is exactly the same proportion as reported
in comparable studies [10, 12, 13, 22]. Comparing the
patient demographics and baseline characteristics to the
first study made by the STESS inventors [10] was neither
indicative for a substantial selection bias. Our cohort had
a lower proportion of acute symptomatic aetiology (38 %
vs. 56 %) but included slightly more elderly patients (48 %
vs. 35 % ≥65 years). The in-hospital mortality of our
patients was actually lower (12 %) than in similar studies
by Sutter et al. (18 %) or Rosetti et al. (21 %) [10, 12], show-
ing that selection bias does not explain the high mortality.
The analysis of the underlying aetiology and the
analysis of patients with refractory SE only (Additional
file 2: Figure S1) did neither provide an obvious explan-
ation for the poor outcome of the patients. The same
applies for an obvious flaw of our study, the very vari-
able follow-up: it may even have masked a higher mor-
bidity. In summary, we think that the high overall
mortality of patients with SE is a matter of fact and not
due to selection bias.
In the light of the very high mortality of patients with
SE after discharge, the prediction of outcome beyond
acute treatment becomes as important as in-hospital
mortality. No previous studies have tested, if STESS (or
other clinically relevant scores) predicts long-term sur-
vival. Our study confirmed the prognostic significance of
the STESS for in-hospital mortality in this Danish cohort
of patients [10, 12]. STESS with a threshold of 4 reliably
identified patients that survived the acute phase of SE,
and predicted to some extend in-hospital mortality. We
here complement current knowledge by showing for the
first time that STESS also predicts overall mortality
(though with a lower sensitivity and specificity) but is
not significantly associated with mortality after dis-
charge. The Kaplan-Meier-plot based on the optimal
cut-off of ≥ 4 in the discharge analysis displays this sig-
nificant difference in overall mortality (Fig. 2a).
All components of the STESS except “history of previ-
ous seizures” remained significantly associated with
long-term survival and survival after discharge. This in-
dicates “history of previous seizures” is solely relevant
for the acute phase of SE, possibly because patients with
acute symptomatic seizures (and no history of previous
seizures) have higher odds of dying in the hospital. Of
note, the differentiation between seizure types remained
without prognostic relevance in all our analyses in line
with the report by Sutter et al. [12].
Among all components, “coma” yielded most prognos-
tic information but only relevant for a few patients.
Coma had higher odds for death (in-hospital mortality:
19.4 and overall mortality: 8.8) than STESS (in-hospital
mortality: 17.3, overall mortality: 5.3) in all our analyses,
suggesting that this factor may even warrant a higher
score. Only 3 out of 19 patients presenting with “coma
at onset” of SE were alive at end-of-follow up.
The other major factor with similar importance was
“age above 65”, which gave 2 points in the STESS. The
Kaplan-Meier curves of patients above and below
65 years (Fig. 2e) were similar to the Kaplan-Meier
curves of patients with STESS ≥3 (or STESS ≥4, Fig. 2b).
However, neither the high mortality of SE patients nor
the plateau after approximately 3 years can be explained
by age alone or by naturally occurring death of the pa-
tients. Assuming that natural occurring death in higher
age would explain the difference alone, one would not
expect a major difference 6 months after SE. However,
this analysis (Additional file 1: Table S3) revealed similar
results as the analysis at the end-of-study. Further, the
Kaplan-Meier curves of patients with STESS ≥3 (or
STESS ≥4) show a much more rapid decline than the
curve of patients above and below 65, which further
supports the idea that STESS bears more prognostic in-
formation than age alone.
It is tempting to speculate that neuronal damage after
SE may be the factor that substantially contributes to
overall outcome of patients with SE. In patients with
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acute neuronal damage (like stroke [23]), age is a major
prognostic factor and neuronal damage may therefore
explain the high relevance of age as prognostic factor.
However, this retrospective study with all its limitations
(e.g. mortality as only outcome parameter, lack of
detailed assessment of functional outcome, retrospective
design, incomplete assessment of other prognostic fac-
tors, etc.) does not provide clear clues in support of this
hypothesis and further studies are required to better
understand the important contributors to long-term
survival after SE beyond aetiology.
Conclusions
In summary, this study supports STESS as a valuable
and easy-to-use tool to estimate in-hospital mortality.
The overall mortality after SE was found higher than
expected compared to previous research. Most of
STESS’ components were found to have an association
to the overall mortality after SE. There are though rea-
sons to believe that other factors may play important
roles for long-term outcome. A prognostic score for
long-term survival may be based on STESS but will
certainly require modifications to improve its ability to
predict long-term survival.
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